Palisade Bio Reports Positive Topline Data From Phase 1b Study Of PALI-2108 In FSCD But Stock Down

Palisade Bio reported positive topline Phase 1b data for PALI-2108 in 5 patients with fibrostenotic Crohn's disease (FSCD). The results constitute early proof-of-concept for the program but are limited by the small sample size (n=5); successful follow-up trials would be required to materially de-risk the asset. Expect the announcement to be modestly positive for the equity, potentially moving the stock on the order of ~1-3% while longer-term value will depend on larger confirmatory studies.

Analysis

Palisade Bio reported positive topline Phase 1b data for PALI-2108 in 5 patients with fibrostenotic Crohn's disease (FSCD). The results constitute early proof-of-concept for the program but are limited by the small sample size (n=5); successful follow-up trials would be required to materially de-risk the asset. Expect the announcement to be modestly positive for the equity, potentially moving the stock on the order of ~1-3% while longer-term value will depend on larger confirmatory studies.